What it is
A small-molecule beta-carboline derivative studied in preclinical neuropharmacology research. Available as a powder.
How it works
Preclinical studies suggest weak monoamine oxidase inhibition along with effects on mitochondrial complex I, dopamine neuron survival, and neurogenesis-related gene expression in rodents.
Where it's used
Studied in preclinical rodent research for proposed effects on dopaminergic signaling and neuroprotection.
Regulatory status
Not FDA-approved; research compound.
Tracking it
9-Me-BC is oral, which makes consistency the whole game — a simple daily check-off with a reminder beats memory every time.
Source
Public reference
Not medical advice. This page is an educational summary compiled from public
sources for people who log what they take. It is not a recommendation to use
9-Me-BC, a dosing guide, or a substitute for a clinician.
How we source →
Last reviewed 2026-06-11